Bioequivalence and Bioavailability Forum

Hi MGR,

do I understand you correctly: You performed a study without knowing (i.e., stating in the SAP) how to evaluate its results? Bad idea. The partial replicate is a lousy design since FDA’s model in the ABE-code – which you have to use if s_WR <0.294 – is overspecified. It some cases any (!) software will fail to converge. Then you have a lot of data and no (!) outcome at all… In the future consider fully replicated designs (TRT|RTR or TRTR|RTRT) instead.

❝ 1. Can we use group effect into the stat analysis?

In the ABE-part, yes. Please search the forum. It would have been better, to follow FDA’s sugges­tion in study planning in order to avoid trouble. If all those conditions were fulfilled in the study you could try to argue not to incorporate group effects (also in RSABE).

❝ 2. if so how we can include those to ilat and dlat?

I don’t see how that could be done.

❝ 3. how can we add group effect into the analysis i.e, glm procedure for calculating the limits?

See one experience with the FDA and a suggestion by John.